Raised seborrheic keratoses (SKs)
are known to appear in highly visible locations

Common treatment modalities

Many patients are willing to
self-pay for SK treatment

*Survey not limited to patients with raised SKs.

The ESKATA Difference

FDA-APPROVED formulation

  • ESKATA contains 40% pharmaceutical grade H2O2 (hydrogen peroxide) that meets FDA guidelines and is FDA-approved for the treatment of raised seborrheic keratoses

  • The active pharmaceutical ingredient is housed in a proprietary solution that increases spreadability while maintaining stability4

  • This unique combination was evaluated in pivotal trials that included over 900 subjects*

Novel Application

  • Doe-foot applicator

  • Applicator tip design allows optimal spreadability over targeted lesions

  • Flame-sealed crushable ampule provides shelf stability for 2 years at room temperature

Order ESKATA now

*ESKATA: 467; Vehicle: 470

References

  1. Data on file. Aclaris Therapeutics, Inc. 2017.

  2. Jackson JM, Alexis A, Berman B, Berson DS, Taylor S, Weiss JS. Current Understanding of Seborrheic Keratosis: Prevalence, Etiology, Clinical Presentation, Diagnosis, and Management. J Drugs Dermatol. 2015;14(10):1119-1125.

  3. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges. 2008;6(8):664-667.

  4. ESKATA Full Prescribing Information. Aclaris Therapeutics, Inc. 2017.

INDICATIONS AND USAGE

ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) is indicated for the treatment of seborrheic keratoses that are raised.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Do not apply ESKATA to the eyes or mucous membranes. Avoid treating seborrheic keratoses within the orbital rim. Direct contact with the eye can cause corneal injury (erosion, ulceration, perforation, and scarring), chemical conjunctivitis, eyelid edema, severe eye pain or permanent eye injury, including blindness. If accidental exposure occurs, flush with water for 15 to 30 minutes, initiate monitoring and further evaluation as appropriate.

Skin reactions occurred in the treatment area after application of ESKATA. Severe local skin reactions included erosion, ulceration, vesiculation and scarring. Do not retreat until the skin has recovered from any reaction caused by the previous treatment.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions include erythema (99%), stinging (97%), edema (91%), scaling (90%), crusting (81%), and pruritus (58%).

CONTRAINDICATIONS

None.

DOSAGE AND ADMINISTRATION

ESKATA is to be administered by a healthcare provider. For topical use only. Not for oral, ophthalmic, or intravaginal use. Not for open or infected seborrheic keratoses.

Please see accompanying full Prescribing Information for ESKATA (hydrogen peroxide) topical solution, 40% (w/w).